where is retatrutide approved Some Providers Prescribe Unapproved for Weight Loss at Alarming Rate Demand for Unapproved Weight-Loss Drug

How often have you sighed at the reflection in the mirror, wishing those extra pounds would magically disappear

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 2326 October 2023: GLP-1 receptor agonists available evidence not supporting link with thyroid cancer

Whether a reduced incretin effect (reduced beta cell sensitivity to GIP and/or GLP-1) may play a role in the pathophysiology of NAFLD warrants further investigations

Semaglutide and tirzepatide do not damage hair follicles

Diabetic ketoacidosis In patients with insulindependent diabetes, the risk of DKA is the primary concern

Your healthcare team will schedule regular reviews to monitor your response and make evidence-based decisions about dose optimisation, ensuring you receive maximum benefit whilst minimising risks